<DOC>
	<DOCNO>NCT01262482</DOCNO>
	<brief_summary>In Spain , gastric carcinoma 5th frequent malignant tumor woman 6th men , represent 3rd cause cancer-related death amongst woman 4th amongst men . The average 5-year survival rate Spain 30 % . The main reason , despite carry adjuvant treatment , 50 % present relapsed disease . Sorafenib first RAF inhibitor , RAF-1 B-rRAF b-RAF variant V600E . Moreover , show ability inhibit tyrosin-quinase receptor VEGFR 2 3 , c-kit , Flt-3 PDGFR . Its activity clearly proven clear cell renal carcinoma . The mechanism Sorafenib seem act existence mutation RAS RAF , VHL shortage HIP produce VEGF , bFGF TGF overexpression produce turn hyper-stimulation RAF/ERK/MEK pathway . The RAF/MEK/ERK pathway angiogenesis seem clearly involve gastric carcinoma tumorigenesis progression . Because , seem interesting associate Sorafenib oxaliplatin-based chemotherapy , show effectiveness relapse patient receive cisplatin-based scheme . Moreover , phase 1 trial confirm tolerance oxaliplatin Sorafenib association , describe partial response amongst gastric cancer patient previously treat cisplatin .</brief_summary>
	<brief_title>Study Oxaliplatin Sorafenib Combination Treat Gastric Cancer Relapsed After Cisplatin Based Treatment</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Gastric gastroesophageal junction adenocarcinoma confirm cytology biopsy , unresectable metastatic disease progress cisplatinfluoropyrimidine base scheme ( excluded neoadjuvant treatment administer without concomitant radiotherapy ) 2 . Older 18 year moment inform consent form signature 3 . Age &gt; 18 year 4 . ECOG 02 5 . Measurable disease RECIST criterion . Lesions measure CTscan MRI 6 . Life expectancy &gt; 12 week 7 . Adequate medullary reserve hepatic renal function , define accord follow parameter : 1 . Hemoglobin ≥ 9g/dl 2 . Neutrophils ≥ 1,5 x 10^9/L 3 . Platelets ≥100 x 10^9/L 4 . Total bilirubin ≤ 1,5 time upper limit normal ( ULN ) 5 . ALT ( GTP ) AST ( GOT ) ≤ 2,5 time upper limit normal ( ULN ) ( ≤ 5 time ULN patient hepatic metastasis ) 6 . PTINRPTT ≤ 1,5 time ULN . ( The patient anticoagulant treatment dicumarin heparin include previous evidence alteration parameter ) 7 . Creatinine clearance &gt; 30ml/min 8 . The patient able understand mean participation trial voluntary give participation consent signing informed consent form 1 . More one line treatment locally advance disease 2 . Active ischemic cardiopathy . History cardiac disease define follow : 1 . Congestive cardiac failure &gt; class 2 NYHA 2 . Active coronary disease . The recruitment patient solve myocardial infarction allow , diagnose least 6 month trial start 3 . Cardiac arrhythmia require treatment antiarrhythmic drug . ( The treatment betaadrenergic antagonist digoxin allow ) 4 . Noncontrolled arterial hypertension 3 . Noncontrolled intercurrent illness 4 . Symptomatic sensitive peripheral neuropathy 5 . Another malignant disease diagnose past 5 year , except situ cervix carcinoma adequately treat , nonmelanoma skin carcinoma , superficial bladder tumor ( Ta , Tis T1 ) , tumor treat curative way 3 year prior recruitment 6 . Pregnant breastfeed woman . Women undergo pregnancy test within 7 day prior recruitment . Both men woman recruit trial use appropriate barrier contraceptive method sexual relation trial period least two week completion . Men participate trial continue use contraceptive method least 3 month treatment completion 7 . Chronic disease : AIDS , Hepatitis B and/or Hepatitis C 8 . Clinically active severe infection ( Grade 2 NCICTC version 3.0 ) 9 . Cerebral metastasis meningeal tumor 10 . Patients require chronic corticosteroid treatment high dos corticosteroid immunosuppressive treatment 11 . Patients undergone major surgery within 4 week prior trial start 12 . Patients complete chemotherapy radiotherapy treatment within 4 week prior clinical trial start ( except palliative radiotherapy , within 2weeks prior clinical trial start ) 13 . Previous treatment use RAS pathway inhibitor 14 . Any medical severe psychiatric condition drug consumption involve serious risk patient take part clinical trial prevent signature inform consent form 15 . Patients unable swallow medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>gastric</keyword>
	<keyword>gastroesophageal junction</keyword>
	<keyword>Relapsed</keyword>
	<keyword>sorafenib</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>